Login
$MGRX
$0.16 +$0.00 (0.75%) After hours

$MGRX 8-K SEC Filings

Filed On Filing
13 Nov 2026 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

As described in Item 5.03, which is incorporated by reference into this Item 3.03, Mangoceuticals, Inc. (the “Company”) amended its Series B and Series C preferred stock designations effective November 9, 2026, and established its Series...

06 Nov 2026 8-K: Submission of Matters to a Vote of Security Holders; Shareholder Director Nominations +1 more

On November 2, 2026, the holder of all 50 issued and outstanding shares of Series B Convertible Preferred Stock (the “Series B Preferred Stock”) of Mangoceuticals, Inc. (the “Company”), acting by written consent in lieu of a meeting, app...

09 Oct 2026 8-K: Entry into a Material Definitive Agreement

This Securities Purchase Agreement (this “Agreement”) is dated as of October 8, 2026 between Mangoceuticals, Inc., a Texas corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its succ...

01 Oct 2026 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more

This Agreement has been executed by the individual or entity whose name is set forth under Section I of “Subscriber Information” below (the “Subscriber”), in connection with the Subscriber’s subscription to purchase ___________ Membershi...

21 Aug 2026 8-K: Termination of a Material Definitive Agreement

Re: Mutual Termination of Business Combination Agreement dated July 29, 2026

04 Aug 2026 8-K: Other Events

Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination

30 Jul 2026 8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +2 more

THIS BUSINESS COMBINATION AGREEMENT (this “Agreement”) is made as of July 29, 2026 (the “Execution Date”),

02 Jul 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

A. Subscription. This Agreement has been executed by __________________________, a/an (Individual/Corporation/LLC/Trust/Partnership), residing and/or having a principal place of business in (Country/State and City) (“Purchaser”, or “Subs...

17 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

This Amendment (this “Amendment”) is made and entered into effective as of March 16, 2026 (the “Amendment Effective Date”), by Mangoceuticals, Inc., a Texas corporation (the “Company”), with respect to each and every Stock Option Agreeme...

23 Feb 2026 8-K: Regulation FD Disclosure

Mangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

19 Feb 2026 8-K: Regulation FD Disclosure

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

06 Feb 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On February 4, 2026, Mangoceuticals, Inc. (the “Company”) received a deficiency notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Na...

19 Dec 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

This Securities Purchase Agreement (this “Agreement”) is dated as of December 18, 2025, between Mangoceuticals, Inc., a Texas corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their respe...

19 Dec 2025 8-K: Entry into a Material Definitive Agreement; Other Events

This Master Service Agreement, including any Order Forms, Schedules and/or Addenda attached hereto (collectively, the “Agreement”), is entered into and effective as of the date of the final signature below (“Effective Date”), by and amon...

10 Dec 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

NOW THEREFORE FOR VALUE RECEIVED, the undersigned, Mangoceuticals, Inc., a Texas corporation (the “Borrower”), hereby promises to pay to the order of The Tiger Cub Trust (the “Holder”), Seventy Five Thousand Dollars ($75,000) (the “Amoun...

14 Nov 2025 8-K: Other Events

Dallas, Texas – November 13, 2025 – Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) is issuing the following clarification regarding its press release issued earlier this morning titled “Mangoceuticals Partners wi...

13 Nov 2025 8-K: Other Events

Mangoceuticals Partners with Eli Lilly and Novo Nordisk to Deliver Affordable Access to Zepbound and Wegovy for Obesity Management

29 Oct 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more

This Lease (this “Lease”) is entered into by and between SVHQ, LLC, a Texas limited liability company (“Landlord”), and MANGOCEUTICALS, INC, a Texas corporation (“Tenant”), and shall be effective as of the date set forth below Landlord’s...

12 Sep 2025 8-K: Departure/Election of Directors or Officers; Compensation

Unless otherwise defined herein, the terms in the Stock Option Agreement (the “Option Agreement”) have the same meanings as defined in the Mangoceuticals, Inc. 2022 (the “Company”) Equity Incentive Plan (as amended from time to time)(the...

02 Sep 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

A. Subscription. This Agreement has been executed by __________________________, a/an (Individual/Corporation/LLC/Trust/Partnership), residing and/or having a principal place of business in (Country/State and City) (“Purchaser”, or “Subs...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support